Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in a report published on Monday morning, MarketBeat reports. The brokerage issued a buy rating and a $50.00 price objective on the stock.

DMRA has been the topic of a number of other research reports. Royal Bank Of Canada started coverage on Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They set an “outperform” rating and a $40.00 price objective on the stock. Wedbush reiterated an “outperform” rating and issued a $35.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, June 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Thursday, June 18th. TD Cowen initiated coverage on Damora Therapeutics, Inc. Common Stock in a report on Monday, June 8th. They set a “buy” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Damora Therapeutics, Inc. Common Stock currently has an average rating of “Moderate Buy” and an average target price of $43.38.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of DMRA stock opened at $29.44 on Monday. Damora Therapeutics, Inc. Common Stock has a fifty-two week low of $2.45 and a fifty-two week high of $38.33. The company has a 50 day moving average price of $25.64 and a 200 day moving average price of $25.86. The stock has a market capitalization of $1.81 billion, a P/E ratio of -5.28 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its earnings results on Wednesday, May 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). On average, research analysts forecast that Damora Therapeutics, Inc. Common Stock will post -1.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Hedge funds and other institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $40,000. Geode Capital Management LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at $266,000. Virtu Financial LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock in the third quarter valued at $49,000. Sigma Planning Corp acquired a new stake in Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at $334,000. Finally, Two Sigma Investments LP purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth about $76,000. 14.20% of the stock is currently owned by institutional investors and hedge funds.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.